4-乙氧基-3-(三氟甲基)苯胺 | 2713-74-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-乙氧基-3-(三氟甲基)苯胺
• 中文别名: 4-乙氧基-3-(三氟甲基)苯胺,97
• 英文名称: 4-ethoxy-3-(trifluoromethyl)aniline
• CAS: 2713-74-8
• 化学式: C₉H₁₀F₃NO
• 分子量: 205.18
• InChiKey: YAIGBJRRAPBODW-UHFFFAOYSA-N

物化性质

• 熔点：
  55.5-56.4 °C(Solv: ethanol (64-17-5))
• 沸点：
  266.1±40.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险等级：
  6.1
• 危险品标志：
  Xi
• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  4-乙氧基-3-(三氟甲基)苯胺 在 盐酸 、 硫酸 作用下， 以 甲醇 、 乙醚 、 水 、 甲苯 为溶剂， 反应 26.5h， 生成 1-(4-ethoxy-3-(trifluoromethyl)phenyl)-1-methyl-3-(naphthalen-1-yl)guanidine
  参考文献：
  名称：

  N′-3-(Trifluoromethyl)phenyl Derivatives of N-Aryl-N′-methylguanidines as Prospective PET Radioligands for the Open Channel of the N-Methyl-d-aspartate (NMDA) Receptor: Synthesis and Structure–Affinity Relationships

  摘要：

  N-Methyl-D-aspartate (NMDA) receptor dysfunction has been linked to several neuropsychiatric disorders, including Alzheimer's disease, epilepsy, drug addiction, and schizophrenia. A radioligand that could be used with PET to image and quantify human brain. NMDA receptors in the activated "open channel" state would be useful for research on such disorders and for the development of novel therapies,: To date, no radioligands have Shown well-validated efficacy for imaging NMDA receptors in human subjects. In order to discover improved radioligands for PET imaging, we explored structure affinity relationships in N'-3-(trifluoromethyl)phenyl derivatives of N-aryl-N'-methylguanidines, seeking high affinity and moderate lipophilicity, plus necessary amenability for labeling with a positron-emitter, either carbon-11 or fluorine-18. Among a diverse set of 80 prepared N'-3-(trifluoromethyl)phenyl derivatives, four of these compounds (13, 19, 20, and 36) displayed desirable low nanomolar affinity for inhibition of [H-3](+)-MK801 at the PCP binding site and are of interest for candidate PET radioligand development.

  DOI：

  10.1021/acs.jmedchem.5b01510
• 作为产物：
  描述：

  2-氯-5-硝基三氟甲苯 在 盐酸 、 氢氧化钾 、 tin 作用下， 以 乙醇 为溶剂， 生成 4-乙氧基-3-(三氟甲基)苯胺
  参考文献：
  名称：

  The Preparation and Reaction of Some Substituted Benzotrifluorides

  摘要：

  DOI：

  10.1021/jo01351a015

文献信息

• [EN] NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME INHIBITEURS DE LA KINASE RÉARRANGÉE AU COURS DE LA TRANSFECTION (RET)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016037578A1

  公开（公告）日：2016-03-17

  This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

  这项发明涉及一种新型化合物，这些化合物是重排转位过程中的抑制剂（RET）激酶，包含它们的药物组合物，它们的制备方法，以及它们在治疗中的使用，单独或结合使用，用于规范胃肠敏感性、蠕动和/或分泌以及/或腹部紊乱或疾病和/或与RET功能障碍相关的疾病或调节RET活性可能具有治疗益处的治疗，包括但不限于所有分类的肠易激综合征（IBS），包括以腹泻为主、以便秘为主或交替排便模式、功能性腹胀、功能性便秘、功能性腹泻、未特指的功能性肠道障碍、功能性腹痛综合征、慢性特发性便秘、功能性食管障碍、功能性胃十二指肠障碍、功能性肛门疼痛、炎症性肠病、非小细胞肺癌、肝细胞癌、结肠癌、髓样甲状腺癌、滤泡性甲状腺癌、间变性甲状腺癌、乳头状甲状腺癌、脑肿瘤、腹腔癌、实体肿瘤、其他肺癌、头颈癌、神经胶质瘤、神经母细胞瘤、冯·希普-林道氏综合征和肾肿瘤、乳腺癌、输卵管癌、卵巢癌、移行细胞癌、前列腺癌、食管和食管胃交界处癌症、胆道癌、腺癌，以及任何具有增加RET激酶活性的恶性肿瘤。
• Cycloalkanecarboxanilide derivative herbicides
  申请人：Shell Oil Company

  公开号：US04166735A1

  公开（公告）日：1979-09-04

  Certain cycloalkanecarboxanilide derivatives are useful as herbicides.

  某些环烷基甲酸苯胺衍生物作为除草剂是有用的。
• Model studies on a synthetically facile series of N-substituted phenyl-N′-pyridin-3-yl ureas leading to 1-(3-pyridylcarbamoyl) indolines that are potent and selective 5-HT2C/2B receptor antagonists
  作者：Steven M. Bromidge、Steven Dabbs、David T. Davies、Susannah Davies、D.Malcolm Duckworth、Ian T. Forbes、Angela Gadre、Peter Ham、Graham E. Jones、Frank D. King、Damian V. Saunders、Kevin M. Thewlis、Deepa Vyas、Thomas P. Blackburn、Vicky Holland、Guy A. Kennett、Graham J. Riley、Martyn D. Wood

  DOI：10.1016/s0968-0896(99)00228-x

  日期：1999.12

  antagonists have been prepared by rapid parallel synthesis. These N-substituted phenyl-N'-pyridin-3-yl ureas were found to have a range of 5-HT2C receptor affinities and selectivities over the closely related 5-HT2A receptor. Extrapolation of simple SAR, derived from this set of compounds, to the more active but synthetically more complex 1-(3-pyridylcarbamoyl)indoline series allowed us to target optimal

  已经通过快速平行合成制备了一系列的5-HT 2C拮抗剂模型。发现这些N-取代的苯基-N'-吡啶-3-基脲比密切相关的5-HT2A受体具有一系列的5-HT2C受体亲和力和选择性。从这组化合物中衍生出的简单SAR外推至活性更高但合成上更复杂的1-（3-吡啶基氨基甲酰基）二氢吲哚系列，使我们能够靶向最佳取代模式并鉴定有效和选择性的5-HT（2C / 2B）拮抗剂。
• Identification of 2-aminothiazoyl piperidine derivatives as a new class of adjuvants potentiating the activity of colistin against Acinetobacter baumannii
  作者：Yuce Chen、Zhen Li、Yu Yin、Ping Yang、Yijin Kong、Zhong Li、Daijie Chen、Xiaoyong Xu

  DOI：10.1016/j.cclet.2022.107948

  日期：2023.2

  approach to solve this problem is to use an antibiotic adjuvant, which is able to potentiate the activity of antibiotic and reduce the dosage of antibiotic. Herein, we reported a novel 2-aminothiazoyl piperidine adjuvant, which enhanced the activity of colistin against Acinetobacter baumannii (A. baumannii). Two pilot libraries of 40 compounds were prepared and their adjuvant activities were evaluated. The

  抗生素耐药性的迅速流行已导致严重的全球健康问题。虽然粘菌素是最后的抗生素，但它受到剂量依赖性毒性的限制。解决这一问题的一个关键途径是使用抗生素佐剂，它能够增强抗生素的活性并减少抗生素的用量。在此，我们报道了一种新型 2-氨基噻唑基哌啶佐剂，它增强了粘菌素对鲍曼不动杆菌( A. baumannii ) 的活性。准备了包含 40 种化合物的两个试验库，并评估了它们的辅助活性。最具潜力的化合物11j能够使 8 µg/mL 粘菌素的最低抑制浓度 (MIC) 降低 16 倍。此外，时间-杀灭曲线显示化合物11j具有显着的杀灭细菌的佐剂活性。预测的ADMET分析表明，2-氨基噻唑基哌啶衍生物具有良好的药物相似性和可接受的理化性质。此外，膜通透性实验表明，化合物11j有利于粘菌素破坏细菌外膜。此外，还进行了比较分子相似性指数分析 (CoMSIA) 和密度泛函理论 (DFT) 计算。从这些分析中得出的结果
• 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP2354134A1

  公开（公告）日：2011-08-10

  [Object] Provided is a compound which has an excellent S1P1 agonist action, and is useful particularly as an active ingredient for an agent for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells. [Means for Solution] According to the present invention, a 2H-chromene compound or a derivative thereof which has an excellent S1P1 agonist action, and is useful particularly as an active ingredient of an agent for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells can be provided. The 2H-chromene compound and a derivative thereof which are the compounds of the present invention have an S1P1 agonist action, and can be used particularly for prevention and/or treatment of a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells.

  [目的]本发明提供了一种化合物，该化合物具有优异的 S1P1 激动剂作用，尤其可用作预防和/或治疗由不良淋巴细胞浸润诱发的疾病或由细胞异常增殖或积聚诱发的疾病的制剂的活性成分。 [解决方法]根据本发明，可以提供一种 2H-色烯化合物或其衍生物，该化合物或其衍生物具有优异的 S1P1 激动剂作用，尤其可用作预防和/或治疗由不良淋巴细胞浸润诱发的疾病或由细胞异常增殖或积聚诱发的疾病的制剂的活性成分。作为本发明化合物的2H-色烯化合物及其衍生物具有S1P1激动剂作用，尤其可用于预防和/或治疗由不良淋巴细胞浸润诱发的疾病或由细胞异常增殖或积聚诱发的疾病。